JP2010514413A - インテグリンα−１１サブユニットに対する結合剤およびその使用 - Google Patents

インテグリンα−１１サブユニットに対する結合剤およびその使用 Download PDF

Info

Publication number
JP2010514413A
JP2010514413A JP2009542211A JP2009542211A JP2010514413A JP 2010514413 A JP2010514413 A JP 2010514413A JP 2009542211 A JP2009542211 A JP 2009542211A JP 2009542211 A JP2009542211 A JP 2009542211A JP 2010514413 A JP2010514413 A JP 2010514413A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
fusion
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009542211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514413A5 (enExample
Inventor
エビー、ルンドグレン‐オーケルルンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cartela R&D AB
Original Assignee
Cartela R&D AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625144A external-priority patent/GB0625144D0/en
Priority claimed from GB0625165A external-priority patent/GB0625165D0/en
Application filed by Cartela R&D AB filed Critical Cartela R&D AB
Publication of JP2010514413A publication Critical patent/JP2010514413A/ja
Publication of JP2010514413A5 publication Critical patent/JP2010514413A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009542211A 2006-12-18 2007-12-18 インテグリンα−１１サブユニットに対する結合剤およびその使用 Pending JP2010514413A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87538806P 2006-12-18 2006-12-18
US87538906P 2006-12-18 2006-12-18
GB0625144A GB0625144D0 (en) 2006-12-18 2006-12-18 Novel binding agents
GB0625165A GB0625165D0 (en) 2006-12-18 2006-12-18 Novel binding agents and uses thereof
PCT/GB2007/004886 WO2008075045A1 (en) 2006-12-18 2007-12-18 Binding agents to the integrin alpha-11 subunit, and uses thereof

Publications (2)

Publication Number Publication Date
JP2010514413A true JP2010514413A (ja) 2010-05-06
JP2010514413A5 JP2010514413A5 (enExample) 2011-02-10

Family

ID=42663774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542211A Pending JP2010514413A (ja) 2006-12-18 2007-12-18 インテグリンα−１１サブユニットに対する結合剤およびその使用

Country Status (6)

Country Link
US (1) US20110256061A1 (enExample)
EP (1) EP2101818A1 (enExample)
JP (1) JP2010514413A (enExample)
AU (1) AU2007335988A1 (enExample)
CA (1) CA2709411A1 (enExample)
WO (1) WO2008075045A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168176A1 (ja) * 2018-03-01 2019-09-06 国立大学法人広島大学 抗インテグリンα１１モノクローナル抗体、およびその利用
JP2023508286A (ja) * 2019-12-20 2023-03-02 モメンタ ファーマシューティカルズ インコーポレイテッド インテグリンアルファ１１ベータ１に対する抗体
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
WO2015035235A1 (en) * 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
JP2025539271A (ja) * 2022-10-24 2025-12-04 フィブロコア セラピューティクス インコーポレイテッド インテグリンアルファ１１に結合する抗体、およびその用途
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522232A (ja) * 2002-04-12 2005-07-28 カルテラ、アクチボラグ ノックアウトマウスおよびそれらの使用
WO2006075784A1 (ja) * 2005-01-13 2006-07-20 Gene Techno Science Co., Ltd. 抗α９インテグリン抗体とその用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2008075038A1 (en) * 2006-12-18 2008-06-26 Bioinvent International Ab Binding agents to the integrin alpha-11 subunit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522232A (ja) * 2002-04-12 2005-07-28 カルテラ、アクチボラグ ノックアウトマウスおよびそれらの使用
WO2006075784A1 (ja) * 2005-01-13 2006-07-20 Gene Techno Science Co., Ltd. 抗α９インテグリン抗体とその用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012063250; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．　１９９９，　２７４（３６），　ｐｐ．２５７３５-２５７４２ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168176A1 (ja) * 2018-03-01 2019-09-06 国立大学法人広島大学 抗インテグリンα１１モノクローナル抗体、およびその利用
JPWO2019168176A1 (ja) * 2018-03-01 2021-04-15 国立大学法人広島大学 抗インテグリンα１１モノクローナル抗体、およびその利用
JP7440718B2 (ja) 2018-03-01 2024-02-29 恭之 横崎 抗インテグリンα１１モノクローナル抗体、およびその利用
JP2023508286A (ja) * 2019-12-20 2023-03-02 モメンタ ファーマシューティカルズ インコーポレイテッド インテグリンアルファ１１ベータ１に対する抗体
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物

Also Published As

Publication number Publication date
AU2007335988A1 (en) 2008-06-26
CA2709411A1 (en) 2008-06-26
US20110256061A1 (en) 2011-10-20
WO2008075045A1 (en) 2008-06-26
EP2101818A1 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
JP6779944B2 (ja) 血漿カリクレイン結合タンパク質
JP2010514413A (ja) インテグリンα−１１サブユニットに対する結合剤およびその使用
JP4914209B2 (ja) ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
RU2613422C2 (ru) Антитело к blys
JP2009525758A (ja) Ｐａｒ−２に結合する抗体
WO2006089141A2 (en) Antibodies against cxcr4 and methods of use thereof
WO2022199590A1 (zh) 一种靶向bcma的纳米抗体及其应用
WO2018081437A1 (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
WO2008075038A1 (en) Binding agents to the integrin alpha-11 subunit
CN114685666B (zh) 抗间皮素纳米抗体及其应用
WO2022143550A1 (zh) 间皮素结合分子及其应用
EP1708961B1 (en) Anti-ip-10 antibodies
WO2023051618A1 (zh) Ctla-4结合分子及其应用
CN101528777B (zh) 抗胞外基质蛋白的rgd氨基酸序列的抗体及其制法与用途
AU2019204295A1 (en) Plasma kallikrein binding proteins
KR101117070B1 (ko) 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN107840886A (zh) Gm‑csf抗体及其用途
HK40006299A (en) Plasma kallikrein binding proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507